Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have been given an average rating of “Hold” by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $2.00.

Several analysts have recently weighed in on HRTX shares. Wall Street Zen raised Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Finally, HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 11th.

Institutional Trading of Heron Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC boosted its position in shares of Heron Therapeutics by 67.5% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 159,997 shares of the biotechnology company’s stock valued at $68,000 after purchasing an additional 64,499 shares during the period. Bank of America Corp DE bought a new stake in Heron Therapeutics in the 2nd quarter valued at $46,000. Ieq Capital LLC bought a new stake in Heron Therapeutics in the 2nd quarter valued at $41,000. Tejara Capital Ltd bought a new stake in shares of Heron Therapeutics in the 2nd quarter worth about $2,779,000. Finally, BlackRock Inc. bought a new stake in Heron Therapeutics during the 2nd quarter worth about $4,503,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Stock Performance

NASDAQ HRTX opened at $0.36 on Tuesday. The firm has a market capitalization of $68.52 million, a P/E ratio of -1.90 and a beta of 1.62. Heron Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $1.57. The company has a debt-to-equity ratio of 24.35, a quick ratio of 1.51 and a current ratio of 2.49. The stock’s fifty day moving average is $0.33 and its two-hundred day moving average is $0.56.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. The company had revenue of $37.67 million during the quarter, compared to analysts’ expectations of $42.19 million. On average, research analysts anticipate that Heron Therapeutics will post -0.14 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology-related supportive care. The company’s products are designed to address patient needs in areas such as postsurgical pain and chemotherapy-induced nausea and vomiting.

Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain, and APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting.